Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06573294 · ClinicalTrials.gov registry record · Phase 1
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
A Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT06573294: Recruiting Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors, sponsored by Genmab.
NCT06573294 is a Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors that is actively recruiting participants, run by Genmab. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06573294, a Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
Conditions Studied
Interventions
- DRUG GEN1057
- DRUG Premedication
Study Locations (5)
Other
- National Cancer Center, Tsukiji 5-1-1 - Tokyo
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC - Madrid
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Barcelona
- Hospital Universitari Vall d'Hebron - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2027-09-21 |
| Phase | Phase 1 |
What NCT06573294 shows while recruiting
NCT06573294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Advanced Malignant Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which GEN1057 is the first listed.
NCT06573294 lists 5 locations in 4 states (Other, Tennessee, Texas).
Frequently Asked Questions
What is clinical trial NCT06573294 about?
NCT06573294 is a clinical study titled "Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors". The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participa...
What is the current status of trial NCT06573294?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-08-28. Estimated completion is 2027-09-21.
What conditions does trial NCT06573294 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors.
What interventions are being tested in trial NCT06573294?
The interventions under investigation include: GEN1057 (DRUG), Premedication (DRUG).
Who is sponsoring clinical trial NCT06573294?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06573294 being conducted?
This trial has 5 study locations across Tennessee, Texas, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06573294's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI